MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two programmes ...

The first new HiLux in 10 years may not be all-new, but it has a bolder look, new features, and a cabin fit for the 2020s.